-
Diabetes "medicine king" sold 1 billion! Yangtze River, China and the United States East China broke the screen of foreign investment, and 14 exclusive proprietary Chinese medicines were sold hot
Time of Update: 2022-11-26
"Yaowang" sold more than 1 billion, Yangtze River, Sino-US East China advanced into the TOP20 brand; 14 exclusive products support 78% of the market for diabetic proprietary Chinese medicine, Baiyunshan ranks in the TOP1, with an amazing rise in Ling, and the new Chinese medicine drugs approved for marketing in 2020 are on the TOP20 list.
-
When innovative drugs give up health insurance
Time of Update: 2022-11-26
When it comes to medical insurance negotiations, what kind of soul bargaining scene will be released this year?However, there was an innovative drug that was completely forgotten, and until Yuheng Group was ruled bankrupt, we remembered the fate of Yuheng Biotechnology (a shareholding company of Yuheng Pharmaceutical) and the 6th domestic PD-1 sepalimab.
-
Summary In 2022, 21 innovative anti-tumor drugs were approved for marketing in China for the first time!
Time of Update: 2022-11-26
Akeso: CardonilimabAkeso: CardonilimabIndications: Cervical cancerIndications: Cervical cancerOn June 29, 2022, it was announced that the National Medical Products Administration of China has approved the new drug application of Kaitanib (Cardunilimab Injection), the world's first PD-1/CTLA-4 bispecific antibody tumor immunotherapy drug independently developed by Akeso, for the treatment of patients with relapsed or metastatic cervical cancer (R/MCC) who have failed previous platinum-containing chemotherapy.
-
MNC's counterattack to the "bill": Lilly ends small molecule drug pipeline, AZ may never launch new cancer drugs in the United States again...
Time of Update: 2022-11-26
With the release of the 2022 Q3 performance report, in addition to summarizing the performance of the past three quarters, some pharmaceutical companies have also responded (counter) to a recently rel
-
The low-priced "Me too" strategy doesn't work in the U.S., and the super unicorn returns to the real world
Time of Update: 2022-11-26
EQRx, an American biopharmaceutical company established in 2020, aims at the demand behind the high prices of innovative drugs in the United States, intending to subvert the American innovative drug industry with low-cost Me too drugs.
-
Behind the prequalification of Sinovac's varicella vaccine, the "SV-1 cell line" is indispensable
Time of Update: 2022-11-26
Different from other approved vaccine products before, the pre-certified Sinovac chickenpox vaccine uses Sinovac's independent intellectual property rights SV-1 cell line, which represents the "breakthrough" achievements of China's independent research and development of vaccines and has gained international recognition and far-reaching significance.
-
K drugs, O drugs look down on "medical insurance life and death", 200 billion PD-1 market, who spends it?
Time of Update: 2022-11-26
The roll does not win, lying and lying uneven. This may be the heart of many PD-1 companies. The roll does not win, lying and lying uneven. This may be the heart of many PD-1 companies. For PD-1, in o
-
The Ministry of Finance spoke again: Fair competition between domestic and foreign enterprises!
Time of Update: 2022-11-26
Products produced in China, regardless of whether their suppliers are domestic or foreign-funded enterprises, should be guaranteed equal rights to participate in government procurement activities in accordance with the law.
-
The "tide" of nucleic acid testing is receding, where is the next outlet in the IVD industry?
Time of Update: 2022-11-26
On November 13, Shanghai also issued a content to optimize and adjust and refine the implementation of relevant prevention and control measures, clarifying that nucleic acid testing for all employees is generally no longer carried out according to administrative regions, and only carried out when the source of infection and transmission chain are not clear, and the community transmission time is long, and the epidemic base is unclear.
-
Without worrying about orders, expanding production capacity is still the main theme, and start-up CDMO enterprises are inventoried
Time of Update: 2022-11-26
Whether it is the entry of new players or the transformation of old players to land in the capital market, the CXO track has always been in the spotlight. In recent months, Arterial New Medicine has n
-
Tonghua Dongbao 2 insulin aspart injections were approved, one of which was the first imitation
Time of Update: 2022-11-26
At present, the domestic listed enterprises of insulin aspart 30 injection include Gan&Lee Pharmaceutical, Zhuhai Federal Pharmaceutical, and Yichang Dongguang Changjiang Pharmaceutical in addition to the original research manufacturers and Tonghua Dongbao.
-
Focusing on the "she economy", domestic and foreign pharmaceutical companies are pouring into the field of women's health
Time of Update: 2022-11-26
, the women's health market will attract more and more domestic and foreign pharmaceutical companies, which will also promote the further development of China's women's health service industry.
-
Deeply linked to global pharmaceutical innovation, how can Shanghai Power help the development of the industry? IBIWS
Time of Update: 2022-11-26
On November 14, the 2nd Shanghai International Biomedical Industry Week was grandly opened in Shanghai. Top experts, scholars and industry innovators shared their thoughts on innovation driving the de
-
There are 0 US stocks, few Hong Kong stocks, A-shares have plummeted by half, and the IPOs of biopharmaceutical companies have gone from breaking to "not being issued", when will it bottom? 2022 IPO summary and outlook
Time of Update: 2022-11-26
" Song Gaoguang said frankly, "Because the most important exit channels are close to closure, it is difficult for the Hong Kong Stock Exchange to issue an IPO, and even if it is issued, the serious valuation inversion in the primary and secondary markets will make investors in the primary market more than worth the loss, and there are many lessons from the past.
-
The diagnostic criteria for hypertension have been lowered, and the drug market may usher in an outbreak
Time of Update: 2022-11-26
6 billion yuan, an increase of 8% year-on-year, and the future market scale continues to expand, and it is expected that the market size of antihypertensive drugs in China will reach 103.
-
8 billion, the "hidden" layout outside the market of the vaccine brother, spreading to dual antibodies, CGT, CXO
Time of Update: 2022-11-26
The vaccine brother is in a difficult period. The vaccine brother is in a difficult period. In 2021, the company's agent (HPV vaccine-related) operating income was 20. 93 billion yuan (a year-on-year
-
Thinking about the reform of medical insurance payment to help the high-quality development of the innovative drug industry
Time of Update: 2022-11-26
com/s?__biz=MzA4MTgyMTA3OQ==&mid=2650415212&idx=1&sn=27e00c096419316e59095954effdc6b2&chksm=8781ac94b0f62582051c7ae3784c4836bd875f9f6dd0a196217c143788cca30a020cf7140193&scene=27 Since its establishment in 2018, the National Health Insurance Administration has relied on the strategic purchasing advantages of the pharmaceutical market, practiced the value-based negotiation concept, and carried out negotiations on the access of the national medical insurance drug list, and a total of 250 innovative and life-saving drugs have been added to the catalog through negotiation, playing a significant role in reducing the drug burden of patients and promoting the accessibility of innovative drugs.
-
2022 China Pharmaceutical Innovation Series (1): Moving against the wind
Time of Update: 2022-11-26
Is it possible for Chinese medicine to turn the turbulent macro situation into an opportunity for self-development?In 2022, BCG's China Pharmaceutical Innovation Task Force once again launched the China Pharmaceutical Innovation Series.
-
Recently, there has been good news in the field of clinical and cooperation in the field of domestic anti-tumor drugs
Time of Update: 2022-11-26
At present, anti-tumor drugs have become a large-scale and fast-growing therapeutic field in the world, including the Chinese pharmaceutical market. Data show that in 2021, the global anti-tumor drug
-
Recently, a large number of pharmaceutical companies are laying out in the field of large health
Time of Update: 2022-11-25
On the evening of November 7, Puli Pharmaceutical issued an announcement that due to the company's business development needs, in order to realize the company's life-based health business layout, the company intends to use its own funds to invest in the establishment of a wholly-owned subsidiary Zhejiang Puli Health Technology Co.
